Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Unknown 39Recruiting 25Completed 21Not yet recruiting 10Active not recruiting 3Withdrawn 2Terminated 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 2

Conditions

Stomach Neoplasms 1Rectal Neoplasms 1Colonic Neoplasms 1Adenocarcinoma 1

Interventions

Cyclophosphamide 389Carboplatin 343Gemcitabine 331pembrolizumab 328Cisplatin 327Paclitaxel 294Radiotherapy 291Docetaxel 285Bevacizumab 249Rituximab 233Capecitabine 221Nivolumab 218Dexamethasone 205Fluorouracil 189fludarabine 177Oxaliplatin 177Pemetrexed 153Doxorubicin 152Irinotecan 147Etoposide 144Leucovorin 143Cytarabine 133Bortezomib 129fludarabine phosphate 128Cetuximab 126Lenalidomide 125Filgrastim 119Erlotinib Hydrochloride 119Temozolomide 111Radiosurgery 110

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Terminated × Interventional × XELOX × Clear all
NCT00127036 2017-03-23

Trial for Microarray Analysis of Colon Cancer Outcome-A (MACCO-A)

H. Lee Moffitt Cancer Center and Research Institute

Phase 2 Terminated
65 enrolled 8 charts
Gastrointestinal

Adenocarcinoma, Colonic Neoplasms, Rectal Neoplasms

NCT01748851 2014-11-04

XELOX Versus FOLFOX for Advanced Gastric Cancer (AGC)

Dong-A University Hospital

Phase 3 Terminated
42 enrolled
Gastrointestinal

Stomach Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡